nelitolimod   Click here for help

GtoPdb Ligand ID: 14711

Synonyms: SD-101 | SD101 | Zorblisa
Immunopharmacology Ligand
Compound class: Nucleic acid
Comment: Nelitolimod (SD-101) is a CpG oligonucleotide that is intended to act as a Toll-like receptor 9 (TLR9) agonist.

Full sequence is:
all-P-ambo-P-thiothymidylyl-(3′→5′)-2'-deoxy-P-thiocytidylyl- (3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P- thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy- P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P- thiothymidylyl-(3′→5′)-P-thiothymidylyl-(3′→5′)-2'-deoxy-P- thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P- thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy- P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P- thiothymidylyl-(3′→5′)-P-thiothymidylyl-(3′→5′)-2'-deoxy-P- thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P- thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy- P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P- thiothymidylyl-(3′→5′)-P-thiothymidylyl-(3′→5′)-2'-deoxy-P- thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P- thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-thymidine
No information available.
Summary of Clinical Use Click here for help
Nelitolimod (SD-101) was initially progressed as a clinical candidate with anti-tumour potential [1]. It was later repurposed for potential to treat epidermolysis bullosa (EB).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01042379 I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Phase 2 Interventional QuantumLeap Healthcare Collaborative
NCT03007732 Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT Phase 2 Interventional University of California, San Francisco
NCT07482787 Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis Bullosa Phase 3 Interventional Paradigm Therapeutics
NCT07482813 An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis Bullosa Phase 3 Interventional Paradigm Therapeutics